Monday, August 17, 2020 4:53:41 PM
Thank you this was a very instructive read..interesting how we see for the defendants (generics Sun and Caraco pharma) Charles B Klein (suprise, surpise).
I agree:
It is truly "error to find a claim obvious before . . . consider[ing] the objective considerations,” or to shift the burden of persuasion to the patentee at any point during its obviousness analysis."
Lets hope the CAFC sees this again with Amrn's Appeal case.
Clearly the CAFC including Judges Prost Newman Dyk felt that just because a determination of prima facie obviousness is made, doesn't mean you then set that decision in stone and wall it off by negating or ignoring or weighing against each other, the secondary objective criteria. These secondary objective criteria are (1) Objective and (2) Secondary only in sequence of consideration not in importance for final obviousness determination. They are the watchmen, the yeomen that guard againgst hindsight bias. One doesn't just throw away the secondary consideration of wearing a seat belt for road safety, just because one made a prior primary obviousness determination of "low safety risk" based on driving a low traffic road on a sunny day. ...Hindsight bias is a poison and the court must avoid it. The skillfull presentation of marginal trivia (that too of dubious scientific quality) as a cumulative evidence of obviousness to combine in the prior art, was the mess that Du got herself into.
In re Merchant, 575 F.2d 865, 868–69 (CCPA 1978); see KSR,
550 U.S. at 421 (“A factfinder should be aware, of course,
of the distortion caused by hindsight bias and must be
cautious of arguments reliant upon ex post reasoning.”
I found this part encouraging from the opinion of these CAFC judges:
Novo next argues that even if the district court correctly allocated the burden of persuasion for obviousness, the record evidence did not support a conclusion of expected results. On appeal from a bench trial on obviousness, we review de novo the court’s the ultimate legal conclusion of whether a claimed invention would have
been obvious, and review the underlying findings of fact for clear error. See Golden Blount, Inc. v. Robert H. Peterson Co., 365 F.3d 1054, 1058 (Fed. Cir. 2004).
Oh please do so again your honors...
HK
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
